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Abstract.  We have isolated a protein from media con- 
ditioned by a  murine marrow-derived cell line (PB6) 
and from mouse marrow supernatants  that antagonizes 
interleukin  3-dependent proliferation of cells in cul- 
ture and reversibly inhibits  DNA synthesis of erythroid 
progenitor cells (BFU-E) in vitro.  This protein, p16 
(monomer Mr  =  16 kD on SDS-PAGE), was purified 
to homogeneity and amino acid sequencing of a poly- 
peptide fragment yielded a  sequence identical to that 
of murine cytosolic Cu,Zn-containing  superoxide dis- 
mutase (SOD).  The identification of pl6 as SOD was 
confirmed by the detection of SOD enzymatic activity 
in pure pl6 fractions, and when a commercial human 
erythrocytic SOD preparation was tested it showed the 
same cell inhibitory activities as pl6.  These observa- 
tions show that superoxide dismutase is able to affect 
the cycling and growth factor responses of hematopoi- 
etic cells, activities that have not previously been as- 
sociated with this enzyme. 
C 
ELL proliferation and differentiation  in general can be 
affected by many growth factors having stimulatory 
(8), inhibitory (31), or multiple (28) effects on their 
targets and showing varying degrees of specificity. Many he- 
matopoietic progenitor  cells have been shown  to be spe- 
cifically stimulated  or inhibited by different factors (1,  10), 
and it may be that the control of proliferation  of the many 
cell types in this  system involves a balancing  of the effects 
of opposing signals. Within the erythroid lineage the prolif- 
eration of late progenitor cells is influenced  by erythropoi- 
etin (27), while early progenitors (BFU-E) can be stimulated 
to proliferate by a variety of factors such as interleukin  3 
(IL 3),  granulocyte-macrophage colony-stimulating factor 
(11), activin (32), and an endogenous burst promoting activ- 
ity (12), with the last two having apparently specific effects 
upon the BFU-E. BFU-E proliferation  can also be inhibited, 
both nonspecifically  (e.g., by interferons;  10), and specifi- 
cally by factors such as inhibin  (32). 
The demonstration that protein from marrow supernatants 
of C57BL/6 mice (B6-MS; 2) and from media conditioned 
by cells of the PB6 continuous murine marrow-derived  cell 
line (PB6-CM; 9) can reversibly  inhibit  DNA-synthesis  of 
BFU-E in vitro led to attempts to characterize the nature of 
the inhibitory effect (3) and purify the factors involved (9). 
Recently we have developed a culture model of the BFU-E 
that  serves as a  cell proliferation assay to screen purified 
fractions for the ability to oppose the effects of IL 3 on de- 
pendent cells (4). In this study we describe the purification 
of a  protein  from PB6-CM and B6-MS which is able to 
both antagonize the effects of IL 3 on dependent cells in cul- 
ture and reversibly inhibit cell cycling of BFU-E. By amino 
acid sequencing  we have been able to identify  this protein 
as cytosolic copper,  zinc superoxide dismutase (SOD  ~ • EC 
1.15.1.1), an enzyme involved  in the protection of tissues 
from the toxic effects of the superoxide radical (13). This un- 
expected identification  was confirmed by tests for SOD ac- 
tivity in inhibitory protein preparations and by the demon- 
stration  that commercially available SOD possesses similar 
activity in both cell inhibitory assay systems. 
Materials and Methods 
Animals, Cells, and Reagents 
The isolation of the PB6 (Pan 136) cell line has been described (30); it is 
an immortalized marrow-derived line of an undetermined and apparently 
nonerythroid lineage.  Cultures  used  for the  production of conditioned 
medium for purifications (PB6-CM) were grown in 0.5-2 liters of serum- 
free ¢~-minimal essential medium (c~-MEM; Gibco Laboratories, Toronto, 
Canada) seeded at a density of 5  x  105 cells/ml, and allowed to grow for 
3-4 d before the medium supernatant was harvested by centrifugation and 
filtered before concentration (see below). The DAd rnurine marrow cell line 
is equivalent to an immortalized BFU-E and was obtained from Dr. L. Guil- 
bert (University of Alberta, Edmonton, Canada). Cells were maintained in 
Iscove's modified Dulbecco's medium (IMDM; Gibc.o Laboratories) plus 
1. Abbreviations used in this paper: HSOD, human erythrocytic superoxide 
dismutase; NRP, negative regulatory protein; SOD, superoxide dismutase. 
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cell-conditioned medium, and during proliferation assays the WEHI-3 CM 
was replaced with IL 3 (ICN Biomedical Canada Ltd., Montreal, Canada: 
dosages expressed in units quoted from the source). Mature C57BL/6Ut 
mice were used for harvesting of marrow ceils and supematants according 
to previously described methods (2). All chemicals and reagents used for 
chromatography  and ell~a'ophoresis  were of HPLC or ultrapure grade; human 
erythrocyfic SOD was purchased from Sigma Chemical Co., St. Louis, MO. 
Ion Exchange Chromatography of  Supernatants 
PB6-CM (initial volume '~20 liters) and B6-MS (initial  volume ~20 ml) 
were concentrated via Amicon Hollowfiber, Centriprep, and Centricon con- 
centrators (molecular mass cutoff =  10kD) to a final volume of <1 mi. The 
buffer was changed to 20 mM "Iris, 2% betaine, 20 mM 2-mercaptoethanol, 
and samples were heat~l to 55°C for 10 rain, cooled to room temperature, 
and centrifuged before loading onto a Mono-Q HR 5/5 column (Pharmaeia 
Inc., Piscataway,  N J) in an FPLC setup. The column was developed against 
start buffer plus 1 M NaC1 at a flow rate of 1 ml/min according to the gra- 
dients indicated in the figures, and outflow samples (1 ml) were collected, 
pooled as indicated, and concentrated. Samples assayed for inhibitory ac- 
tivity had the buffer changed to culture medium appropriate to the assay and 
were sterilized by filtration (Millex GV  0.22  /zm).  Protein amounts  in 
purified fractions were determined  by amino acid analysis or estimated from 
band intensity on SDS-PAGE gels relative to standards. 
Electrophoresis and Electroelution of  Proteins 
Isolation of protein from complex fractions for bioassays was done by elec- 
troelution from Laemmli 15%  acrylamide SDS-PAGE gels using the Bio- 
Pad  mini  electrophoresis  system  and  electroelution  module  (Bio-Pad 
Laboratories,  Richmond,  CA),  electroeluted protein samples were put 
through several concentration and resuspension cycles to remove SDS and 
change the buffer to culture medium before being assayed for inhibitory ac- 
tivity. Gels used to visualize the low molecular weight region of crude and 
purified fractions and in the preparation of protein and polypeptide frag- 
ments for sequencing contained 20 % acrylamide and were prepared and run 
according to the method of Giulian and Graham (14), with reducing condi- 
tions. The molecular mass markers used were prestained SDS-PAGE stan- 
dards (1%130 kD; Bio-Pad Laboratories) and the polypeptide molecular 
mass calibration kit (<17 kD; Pharmacia). Gels were silver stained to visual- 
ize proteins, dried with Bio-Gel Wrap (Biodesign, Inc., Carmel, NY) and 
photographed via transmitted light. 
Peptide Mapping and Amino Acid Sequence Analysis 
Peptide mapping was done by running protein preparations on SDS-PAGE 
polypeptide gels, excising the desired protein size region, and performing 
in situ cyanogen bromide cleavage (24) using a modified protocol (15) in 
which the gel slices were soaked in 70% formic acid plus 50 mg/ml CNBr 
for 2 h at room temperature, then equilibrated in stacking gel buffer (14). 
The digested slices were soaked in hot sample buffer (14) for 10 rain and 
the polypeptide fragments were resolved on a second gel identical to the 
first. These conditions consistently gave >70%  cleavage of protein in the 
gel slices. 
Samples of intact protein and cleavage products used for amino acid se- 
quence analysis were recovered by electroblotting from SDS-PAGE gels 
onto Immobilon PVDF membrane (Millipore-Continental Water Systems, 
Bedford, MA), blotted protein was visualized by Coomassie blue staining 
(19) and excised on the membrane support for direct amino-terminal amino 
acid sequence analysis in a gas phase sequencer (model 470A; Applied Bio- 
systems, Inc., Foster City, CA) with online PTH amino acid analyzer. 
Cell Proliferation Assay for IL 3 Antagonism 
The details of this assay have been described (4). It involves testing protein 
samples for the ability to inhibit the proliferation of DA-1 ceils in the pres- 
ence of a growth-permissive  dose of IL 3. This inhibitory effect is expressed 
as the % inhibition (DA-I), equal to the difference between mean living cell 
numbers at 48 h in treated culture wells and untreated controls expressed 
as a percentage of control. The apparent toxicity of a sample is calculated 
as the difference in the mean proportion of dead cells between tested and 
control groups expressed as a percentage of control. Significance of inhibi- 
tion and toxicity relative to controls were determined via comparisons of 
raw cell count data with Student's t test. 
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Figure 1. Inhibitory activity of B6-MS fractions isolated via Mono-Q 
ion exchange chromatography atpH 7.2.8 mg of protein was loaded 
onto the column developed according to the gradient shown. Ali- 
quots (1-3/zg) of fractions were assayed for inhibitory activity and 
the results are shown in the histograms below the tracing (the width 
of each bar indicates the region on the tracing from which the sam- 
pies tested were pooled, all fractions are shown to have some activ- 
ity to distinguish regions where no material was tested). Only the 
flow-through and first early eluting fractions that were active in the 
BFU-E assay were tested in the DA-I assay. SDS-PAGE analysis of 
the flow-through fraction is shown in Fig. 3. 
BFU-E Cell Cycling Inhibition Assay 
The details of this assay have been described (2). It is used to detect rapid 
short-term inhibitors of DNA synthesis by their ability to reduce the lethal- 
ity to BFU-E of brief exposure to the S-phase specific cytotoxin hydroxy- 
urea (HU). Aliquots of marrow cells treated with the test sample are divided 
into two groups and one is exposed to HU, then both (+HU and -HU) are 
washed, cultured, and scored after 7 d for number of erythroid bursts (4-6 
plasma cultures per group). The inhibitory effect of  a tested sample (% inhi- 
bition BFU-E) is calculated as the difference in the percentage of BFU-E 
killed (the difference in mean burst counts between +HU and -HU groups 
expressed as a percentage of the -HU mean) between the test group and 
an untreated control. If there is no significant decrease in -HU burst counts 
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Figure 2. Inhibitory effects  of early eluting PB6-CM Mono Q frac- 
tions. 8 rag of soluble protein was loaded onto the column devel- 
oped against the NaCI gradient indicated at pH 7.5 (note the absor- 
bance scale changes from 0.2-0.5 U full scale). Results from DA-1 
cell proliferation assay for aliquots (0.2-5 t~g) of pooled early elut- 
ing fractions are  shown below the tracing,  and inhibition was 
significant  for the flow-through  and first two early eluting peak frac- 
tions (I and II; shown in SDS-PAGE gels in Fig. 3). 
between test and control then the  %  inhibition (BFU-E) represents the 
proportion of BFU-E that were removed from DNA synthesis during HU 
treatment by the effects of  the test sample. Significance of inhibition was de- 
termined by comparing the numbers of +HU bursts for tested and control 
groups (t test), with an increase versus control indicating inhibitory activity. 
Assay of Superoxide Dismutase Activity 
SOD activity in purified fractions was measured using the negative assay 
of Martin et al. (18), which detects SOD activity through interference with 
the autoxidation of hematoxylin. The reactions were carried out in 2-ml dis- 
posable cuvettes at 25°C with an initial hematoxylin concentration of 200 
/~M added to reaction buffer (50 mM potassium phosphate, 0.1 mM EDTA 
at pH 7) containing the sample to be tested, and the rate of hematoxylin 
autoxidation was monitored as an increase in absorbance at 560 nm in a 
spectrophotometer (model DU-gB; Beckman Instruments, Inc., Palo Alto, 
CA). The SOD activity of a fraction was measured as the decrease in rate 
of change in absorbance it produced expressed as a percentage of the buffer 
alone control (% inhibition). Comparisons of SOD activity in various frac- 
tions were also made using a gel activity assay (5) on samples run in native 
PAGE gels. The human erythrocytic SOD preparation tested for comparison 
had an activity of 3,130 U/rag in the standard xanthine oxidase-cytochrome 
C  assay for SOD activity (20). 
Results 
Fractionation of Supernatants  by Ion 
Exchange Chromatography 
The results of inhibition assays of fractions obtained from 
B6-MS after Mono Q fractionation (at pH 7.2) are summa- 
rized in Fig. 1. BFU-E inhibitory activity comparable to that 
of the starting material was consistently recovered in flow- 
through and early gradient eluting fractions (Fig. 1, center), 
and  samples  from this  range  were  also  inhibitory when 
tested in the DA-1 cell proliferation assay (bottom). SDS- 
PAGE analysis of these fractions (not shown) detected strong 
protein bands in several size ranges, and the major proteins 
were identified by amino acid sequencing to be serum trans- 
ferrin, aspartate amino transferase, c~ and/~ globin, none of 
which had inhibitory activity when tested alone (data not 
shown). 
PB6-CM Mono Q fractions showed a similar distribution 
of inhibitory activity to those obtained from B6-MS, and our 
purification efforts were concentrated on this material since 
it is qualitatively the less complex of the two.  Attempts to 
isolate active components from the Mono Q  early eluting 
fractions via successive application of different chromato- 
graphic methods met with some success, however,  it was 
found that altering the elution gradient and running pH dur- 
ing Mono Q separation was the most effective way to isolate 
inhibitory PB6-CM fractions containing small numbers of 
different proteins as determined by SDS-PAGE. In the Mono Q 
purification shown in Fig. 2 (run at pH 7.5) inhibitory activ- 
ity in the DAol cell proliferation assay was localized to the 
flow-through and early eluting peak fractions, one of which 
(Fig. 2, peak//) consistently showed a single major protein 
band at Mr =  16 kD (referred to hereafter as pl6) on SDS- 
PAGE (Fig. 3). 
Inhibitory Activity of  pl6 Protein 
The IL 3 antagonistic and toxic effects of test samples can 
be distinguished in the DA-1 cell proliferation assay if there 
are  sample  concentrations where  cell  growth  is  reduced 
without an accompanying increase in death. Such an analysis 
is shown in Fig. 4 for t)16 from PB6-CM, which had an in- 
hibitory effect at concentrations where there was no apparent 
toxicity. I)16 was able to oppose the effects on DA-1 cells of 
a  growth-permissive dose of IL 3  (1:5,000  dilution from 
stock equivalent to 1 CFUc U/ml) down to a concentration 
of 60 ng/ml (the high apparent toxicity for larger doses of 
pl6 may be due to pl6 actually causing cells to be starved 
for IL 3). pl6 is also inhibitory in the BFU-E assay (Table 
I) down to a concentration of 45 ng/ml. 
As the gel photograph in Fig.  3 shows, the pl6 protein 
band is present in other Mono Q fractions from PB6-CM and 
B6-MS which show inhibitory activity (Figs. 1 and 2). The 
identity of pl6 protein present in these fractions was estab- 
lished via peptide mapping of the protein bands, and when 
protein from the pl6 region (15-25 kD) was isolated by elec- 
troelution it showed inhibitory activity comparable to that of 
the total fractions (Table I). Protein from the only other size 
region  showing matching bands  in  PBt-CM  and B6-MS 
(70-90 kD, containing mostly serum albumin and transfer- 
rin) did not show inhibitory activity (Table I). 
Sequence Analysis and Identification  of  pl6 
Intact pl6 did not yield a sequence when analyzed in the se- 
quencer and the results were consistent with a protein having 
a blocked NH~ terminal. When the major 12-kD  fragment 
obtained after CNBr cleavage of pl6 was analyzed the fol- 
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Figure 4. Dose vs. inhibitory  effect  and apparent toxicity  in the DA-I 
cell proliferation assay for p16 protein purified from PB6-CM (see 
Materials and Methods for calculations). Undiluted initial p16 con- 
centration was 4 tLg/ml. 
Figure 3.  SDS-PAGE gels of lower molecular weight region for 
samples corresponding to the flow-through  and first two early elut- 
ing Mono Q protein peaks from PB6-CM (Fig. 2) and the Mono Q 
flow-through  fraction of B6-MS (Fig. 1). Mohilities of p16 protein 
and size standards are shown to the right. 
lowing sequence was obtained (with a 93 % repetitive yield) 
for the first 20 amino acids: 
KAVXVLKGDGPVQGTIHFEQ. 
MAMKAVCVLKGDGPVQGTIHFEQLA 
is the amino acid sequence deduced from the first 25 codons 
of the cloned eDNA for mouse cytosolic CuZn-superoxide 
dismutase (SOD; 7), which has an unmodified chain molec- 
ular mass of 15,943 D and was found as a match to the p16 
sequence during a computerized search of  the NBRF protein 
sequence data base. The unknown amino acid at position 4 
(X) in the p16 fragment sequence corresponds to cysteine (C) 
in SOD, and cysteine is not detected during sequencing un- 
less it is first modified to a stable derivative, which was not 
done in this instance. The residue preceding the NH2 termi- 
nal of the p16 fragment is a methionine (M) in SOD, which 
is consistent with the fact that CNBr cleaves proteins at M-X 
bonds, and the expected size of the major CNBr fragment 
from SOD of 115 amino acids ('~11.9 kD) matches that ob- 
tained from p16. 
SOD Activity of  pl6 
The results of SOD activity testing for the commercially  pre- 
pared human enzyme, p16 protein, and PB6-CM are shown 
in Table II. PB6-CM and p16 purified from it clearly show 
SOD activity, and a p16 concentration of ~200 ng/ml (total 
reaction volume =  2 ml) is sufficient to inhibit the autoxida- 
tion of 200 pM hematoxylin by 95 %. While it may be that 
enzymes from different sources will not show the same activ- 
ity in the assay, a rough estimate of p16 SOD activity can be 
made by comparing its activity to that of human erythrocytic 
SOD, for which five standard SOD activity units (20) inhibit 
hematoxylin autoxidation by 77 % (Table II). This compari- 
son gives an activity of •70  ng p16 per standard SOD activ- 
ity unit (20), which is greater than the activity of the human 
SOD preparation (300 ng protein per unit), but comparable 
to the activity seen for highly purified SOD (12 ng/U; 26). 
Matching the levels  of inhibition seen  for PB6-CM  with 
equivalently active amounts of p16 gives an average estimate 
of p16 concentration of 1 ng/ml, which is in agreement with 
the estimates of p16 in PB6-CM obtained from silver-stained 
SDS-PAGE  (data not shown). 
Inhibitory Activity of  Superoxide Dismutase 
Human erythrocytic SOD (HSOD) was tested for inhibitory 
activity in the DA-1 cell proliferation assay, with the results 
shown in Table IlL'Like pI6/SOD tested in the same assay 
(Fig. 4), HSOD showed strong inhibition and apparent toxic- 
ity at high concentration and an intermediate range of con- 
centrations which produced significant inhibition vs,  IL 3 
with low apparent toxicity. 
Table I. Inhibitory Effects of  Purified Fractions 
Percent 
Fraction tested  Concentration  inhibition 
/zg/ml 
DA-1 proliferation assay 
B6-MS Mono Q 
Flow-through 
Flow-through 15-25 kD 
Early eluting 
Early eluting 15-25 kD 
Early eluting 70-90 kD 
PB6-CM Mono Q 
Early eluting I 
Early eluting I 15-25 kD 
BFU-E suicide assay 
p16 from PB6-CM 
2.5  15" 
0.1  20* 
1.0  29* 
0.1  18" 
1.0  9 
1.0  17" 
0.2  24* 
0.1  45 * 
0.045  13" 
0.015  1 
* P  <  0.05 (see Materials and Methods) percentages are averages from two 
teSt groups. 
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and Controls* 
Sample  Rate of  Percent 
tested  hematoxylin  autoxidation  inhibition 
A56o U/min  x  10  -J (SE) 
Control  44.8  (0.7)  0 
Human SOD  5 U  10.3 (0.2)  77.0 
p16  600 ng  1.8 (0.4)  96.1 
400 ng  2.1 (0.2)  95.3 
300 ng  11.9 (2.3)  73.4 
200 ng  20.4 (3.9)  54.5 
150 ng  40.0 (3.4)  10.7 
PB6-CM*  300 x  3.0 (0.6)  93.4 
167x  16.4 (1.3)  63.4 
60x  29.9 (1.4)  33.3 
* Total reaction volume was 2 ml; see Materials and Methods for calculations. 
¢ Concentrations  given are relative to freshly harvested  PB6-CM;  60x  con- 
centrated  PB6-CM is effective in both cell inhibition assays. 
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Figure 5. The inhibition of DA-1 cell proliferation by human CuZn 
SOD (HSOD) is reversible by the addition of IL 3. Arrows indicate 
times at which all cultures had IL 3 (0.5 U/nil) added, and the test 
group was also given HSOD (50 U/ml) at the first two feedings. Cell 
counts are averages from two groups. 
The  original  demonstration  that  PB6-CM  was  an  an- 
tagonist to IL 3 involved an experiment similar to the DA-1 
cell proliferation assay wherein the cultures were carried for 
several days and given intermittent "feedings" of IL 3 (4). 
The successive additions of IL 3 were able to overcome the 
initial effects of the inhibitor, allowing the treated cultures to 
"catch up" to the control, a further demonstration that the in- 
hibitor was not merely killing cells. The results of such an 
experiment done with HSOD are shown in Fig.  5 and the 
results parallel those seen for PB6-CM under similar condi- 
tions (4). 
The inhibitory effect of HSOD on BFU-E is shown in Fig. 
6, and again it is clear that HSOD has an inhibitory effect 
in this assay (the protein concentration was equivalent to 300 
ng/U of SOD activity). The results for pl6/SOD from Table 
I are plotted for comparison, and the two SOD preparations 
show similar dose-response profiles in this assay. 
We have also made direct comparisons of the amounts of 
SOD activity present in various fractions using a gel activity 
assay (5), which confirm that there is sufficient SOD present 
in PB6-CM (,,o0.08 U/ml for unconcentrated CM) and B6- 
MS (,,ol.3 U/ml) and the fractions derived from them to ac- 
count for the inhibitory activities observed. This analysis did 
not detect the presence of any SOD species other than the 
cytosolic Cu,Zn form in any of the preparations used in this 
study. 
Discussion 
In this study we have shown that a protein, p16, is present 
Table IlL Results of  DA-1 Proliferation Assay for Inhibitory 
Activity of Human Erythrocytic SOD 
Percent 
Concentration  inhibition  Toxicity 
U/ml 
200  32*  47 
100  14"  5 
50  18"  7 
10  3  0 
* P <  0.05  see Materials and Methods for calculations. 
in the marrow supernatant of C57BL/6 mice (B6-MS), in 
serum-free medium conditioned by the growth of the PB6 
cell line (PB6-CM), and in fractions isolated from either via 
ion exchange chromatography or electroelution that are able 
to reversibly inhibit BFU-E cycling and oppose the stimula- 
tory effects of IL 3  on  DAd  cell proliferation.  We have 
identified the major protein present in p16 preparations as 
murine CuZn SOD on the basis of its amino acid sequence 
and enzymatic activity and we have also shown that a com- 
mercial preparation of human erythrocytic SOD displays in- 
hibitory characteristics similar to pl6/SOD, PB6-CM, and 
B6-MS. These facts make it reasonable to propose that SOD 
present in PB6-CM and B6-MS is responsible for their ob- 
served inhibitory effects. 
It is unclear what the relationship is between pl6/SOD and 
preparations (negative regulatory protein or NRP;  9) that 
have been partially purified from media supernatants of PB6 
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Figure 6.  Inhibitory etfects of different concentrations of human 
SOD and pl6/SOD on BFU-E as measured in the BFU-E suicide 
assay (data for p16 from Table I).  Inhibition by human SOD is 
significant for each point (P < 0.05). 
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lar activity to pl6/SOD in the BFU-E inhibition assay. SOD 
exists as a homodimer of Mr  =  32 kD and the inhibitory 
component of NRP is reported to have an Mr =  79 kD on 
gel filtration, and while the partially purified NRP was not 
tested for SOD activity, SOD was certainly present in the cell 
culture supernatants used for NRP purification, both murine 
SOD from the PB6 cells and bovine SOD present as a normal 
constituent of FCS. We found no evidence for the presence 
of any inhibitor other than SOD in PB6-CM, B6-MS, or any 
of  the fractions isolated from them that were examined in this 
study. Assays of protein isolated from the 70-90-kD region 
of inhibitory fractions gave no indication of inhibitory mate- 
rial in this size range (Table I), and direct enzyme assays 
showed that there is sufficient SOD activity present in PB6- 
C M, B6-MS, and the fractions isolated from them to account 
for their inhibitory effects on cells. We also found that only 
the cytosolic Cu,Zn form of SOD was present in our crude 
material, with no other isozymes (see below) detected. 
Superoxide dismutase exists in mammals in three different 
forms:  a  mitochondrial manganese-containing form (Mn- 
SOD; 13), and two copper-zinc forms, one cytosolic (CuZn- 
SOD,  13) and one extraceUular (EC-SOD,  17).  These dis- 
tinct enzymes share a common activity and presumably also 
the important role of shielding living tissues from the toxic 
effects of the superoxide radical by catalyzing the reaction 
202-  +  2H+--*H202 +  02. SOD activity has been reported 
to affect cell differentiation (6, 23), tumorigenesis (22), and 
tumor promotion (16),  and reactive oxygen intermediates 
have been  shown to  affect hematopoietic progenitor cell 
renewal in culture (21). Within the erythroid lineage, the ad- 
dition of CuZn SOD to the culture media of Friend erythro- 
leukemia cells induces differentiation (6), however,  to our 
knowledge SOD has not been implicated in the control of 
normal progenitor proliferation nor in the response of cells 
to growth factors, thus the demonstration here that SOD can 
inhibit the cycling of BFU-E and oppose the effects of IL 3 
on responsive cells in vitro is novel. 
The present line of investigation arose from the observa- 
tion that the majority of marrow BFU-E in C57BL/6 mice 
are normally in a noncycling state (29), but a large propor- 
tion enter DNA synthesis when they are removed from the 
influence of B6-MS in vitro (2).  The addition of B6-MS is 
sufficient to inhibit DNA synthesis in both B6-derived BFU-E 
and those derived from another strain (B6S) in which a high 
proportion of BFU-E are normally in cycle, while B6S-MS 
has no inhibitory effect on BFU-E (2). It has been proposed 
that the factor(s) giving rise to these in vitro effects are re- 
sponsible for the differences in BFU-E cycling state seen in 
the two strains, and the possible role of SOD in this phenom- 
enon is currently under investigation. The inhibitory effects 
of B6-MS are specific for BFU-E, with stem cells elsewhere 
within the erythroid and other myeloid lineages being un- 
affected (2), and we have evidence that like B6-MS, SOD 
does not affect the cycling of other progenitors (i.e., CFU-E, 
CFU-GM, CFU-S) at concentration levels where it is effec- 
tive on BFU-E (Pluthero, E  G., M. Shreeve, D. Eskinazi, 
an~xelrad,  manuscript submitted for publication). 
PB6-CM is able to inhibit the proliferation of other cell 
lines that require IL 3 (like DA-1 cells), while those that do 
not are unaffected (4), and we are testing whether the same 
linking of inhibitory effect to IL 3 dependence will hold true 
for SOD.  While we have only looked at the effects of one 
SOD isozyme in this study, if it is the enzymatic activity of 
the protein that is responsible for the inhibitory activities we 
have observed, then other isozymes should show similar be- 
havior in  our assay systems, and experiments with other 
mammalian and bacterial SODs indicate this is so (Pluthero, 
E  G., and A. Axelrad, manuscript in preparation). 
The molecular mechanisms by which pl6/SOD exerts  its 
effects in the systems so far examined are unknown; one pos- 
sibility may be that superoxide is involved in the transduction 
of signals from stimulatory factors such as IL 3,  and its 
removal by SOD can interfere with cell stimulation. How- 
ever it acts, the demonstration that SOD is capable of inhibit- 
ing the cycling of BFU-E in vitro and possibly in vivo is an 
indication that the control of cell proliferation and differenti- 
ation may involve components of the physiological milieu 
that are not discrete signal factors in the classical sense, but 
yet can have similar effects  through less well-understood 
means. 
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